An Observational Study of Avastin (Bevacizumab) and Interferon Alpha 2a in Patients With Metastatic Renal Cell Cancer (VERA)

An Open Label, Prospective, Observational, Local, Non-interventional Study of BeVacizumab (Avastin) and IntErpherone (IFN) Alpha 2a in Patients With Metastatic and Locally Advanced Renal Cell CAncer (VERA Study)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01392729

Enrollment

Registered

2011-07-12

Start date

2010-09-30

Completion date

2015-06-30

Last updated

2016-11-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal Cell Cancer

Brief summary

This prospective observational study will evaluate the efficacy and safety of Avastin (bevacizumab) in combination with interferon alpha 2a in patients with previously untreated metastatic renal cell cancer. Data will be collected from each patient for up to 4 years.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Adult patients, \>/= 18 years of age * Histologically confirmed metastatic renal cell cancer, clear cell type * Eligible for treatment with Avastin and interferon alpha 2a according to local prescribing information

Exclusion criteria

* Contraindications for Avastin or interferon alpha 2a treatment according to local Summary of Product Characteristics * Known hypersensitivity to Avastin and/or interferon alpha 2a or any of its excipients

Design outcomes

Primary

Measure	Time frame
Progression-free survival	approximately 4 years

Secondary

Measure	Time frame
Overall survival	approximately 4 years
Response rate	approximately 4 years
Safety: Incidence of adverse events	approximately 4 years

Countries

Romania

Outcome results